drugset / Trial / NCT00902460

CP-690,550 and Midazolam Drug-Drug Interaction Study

NCT00902460

Phase 1 Completed 25 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

CP-690,550 and midazolam are metabolized by similar enzymes in the liver. This study is designed to assess whether co-administration of CP-690,500 and midazolam will effect the metabolism of midazolam in healthy volunteers.

Timeline

Start
2009-06
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 2 mg Oral
Subject Tofacitinib Small molecule 30 mg

Indications

No indication recorded.